Search

EHA Congratulates the 2021 Bilateral Collaborative Grant Winners

The Hague, April 25, 2022 –EHA congratulates four talented researchers in Hematology on their receipt of the inaugural EHA Bilateral Collaborative Grants 2021 after a rigorous selection process.

Read more

How to apply for the EHA Mentorship Program

EHA Portal accountTo apply, either as a mentor or a mentee, you must be registered on the EHA Portal (Fluxx).

Read more

Highlights of Past EHA (HOPE ) Asia 2021 - report

In the first weekend of September (September 3-4), EHA opened the virtual platform for HOPE Asia 2021.

Read more

Publication of EHA Annual General Meeting 2024 minutes

The 2024 EHA Annual General Meeting (AGM) took place in the vibrant city of Madrid, Spain, on June 14, 2024. Scheduled on Friday during the EHA Annual Congress, the meeting was once more in a hybrid format.

Read more

Highlights of Past EHA (HOPE) Latin America 2020

EHA and the Argentinian Society of Hematology (SAH) are very happy to announce that the Highlights of Past EHA (HOPE) Latin America 2020 will take place on November 13, 2020 in a virtual format.

Read more

Burnout - it doesn't just happen to someone else

Burnout - it doesn't just happen to someone else

By Dr. med.

Read more

HARMONY: Big data for better and faster treatment

HARMONY Alliance: A European Network of Excellence for Big Data in Hematology - Enabling Better and Faster Treatment based on Big Data technologies
Despite data being a key driver for modern evidence-based medicine, we have been struggling with the same challenge for…

Read more

Hospital pharmacists and regulators lead the way on shortages

EHA welcomes initiatives but calls for more focus on causes

Medicine shortages have a negative impact on the quality and cost of treatments and on patient access to the best possible care.

Read more

Does the patient with myelofibrosis feel better through Pacritinib?

Pacritinib is an oral next-generation multikinase inhibitor with specificity for JAK2 and FLT3 being evaluated to treat myelofibrosis in two Phase 3 trials.

Read more